Biomanufacturing Strategies for Accelerated Modular Scale-Up and Supply

Reliable access to biologics and vaccines increasingly depends on manufacturing infrastructures designed for flexibility, redundancy and rapid scalability. In a context of volatile demand, evolving platforms and heightened expectations around security of supply, biopharmaceutical companies must rethink how manufacturing capacity is designed, operated and expanded.

This webinar explores how engineered flexibility in biomanufacturing enables faster development timelines, resilient supply chains and smoother transitions from clinical to commercial production.

Drawing on more than five decades of experience in vaccine and biologics manufacturing, the featured speakers will present a practical framework for understanding and implementing manufacturing flexibility across the full product life cycle.

The session will examine how flexible capacity can be built into facilities, utilities, workflows and workforce models to respond effectively to changing market and regulatory demands. Particular attention will be given to how flexibility operates at different levels, scaling existing products, onboarding new products within the same platform and switching across platforms when required.

The webinar will also highlight how modular facility design, standardized production blocks and extensive use of single-use technologies enable rapid scale-up and efficient changeovers while maintaining high quality and biosafety standards.

Attendees will gain insight into how segregated material and personnel flows, independent utilities and built-in redundancy contribute to both agility and reliability, even under stressed conditions.
Beyond infrastructure, the presentation will address the organizational elements required to make flexible manufacturing work in practice. This includes competency-based workforce training, integrated development and manufacturing ecosystems, and close coordination across development, GMP production and logistics. Real-world examples will illustrate how these principles translate into tangible benefits for CDMO partners, including accelerated development, reduced tech-transfer risk and enhanced security of supply.

Register for this webinar to learn how flexible biomanufacturing strategies can help accelerate development timelines, reduce supply risk and build more resilient biologics programs.

Speakers

Jordi Ruano, Executive Director of Operations, Human Health Division, HIPRA

With over 25 years of experience in the biotechnology sector, Jordi Ruano has built a solid track record in the design, scale-up and operation of biotech facilities and processes under current EU Good Manufacturing Practices (GMP). His career has encompassed leadership in upstream and downstream processing, as well as extensive expertise in the manufacturing of complex biological products, including viral antigens, recombinant proteins produced in mammalian and microbial systems, antigens derived from SPF embryonated eggs and antigens from parasites. In addition, he has overseen formulation, aseptic filling and lyophilization of vaccines and pharmaceutical products.

Jordi currently serves as Executive Director of Operations, Human Health, at HIPRA, where he leads operational strategy and execution to support the company’s growing human health portfolio. In this capacity, he is responsible for ensuring operational excellence across manufacturing, quality, supply chain and process improvement activities, while fostering innovation and scalability to meet global health needs.

Message Presenter

Brandon Vail, Business Development Officer, HIPRA Biotech Services

Brandon brings deep experience in biologics R&D, clinical development, commercialization and business development, as a trained Chemical Engineer with over 28 years of expertise gained at Amgen, Merck & Co., KBI Biopharma, MilliporeSigma and independent consulting. He has led high-performing teams for innovator biopharma organizations, leading CMC-enabling workstreams including process development, analytical development, tech transfer and MSAT for microbial- and mammalian-based recombinant drug substance programs. Rooted in his technical background, Brandon led technical sales, business development and marketing at multiple contract services organizations, specializing in bridging technical and business value propositions and creating strategic relationships with key clients. Brandon currently serves as the Business Development Officer for HIPRA Biotech Services, the CDMO business unit of HIPRA, leading prospecting, new customer acquisition, pipeline development, key account development, contract negotiation and long-term partnership relations. In this role, he specializes in developing focused understanding of client needs and aligning solutions from the CDMO offering.

Message Presenter